A gas, an amino acid, and an imposter: The story of nitric oxide, l‐arginine, and ADMA in portal hypertension
Daniel A. Langer, Vijay H. Shah – 29 November 2005
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee
Jin‐Won Youn, Su‐Hyung Park, Dimitri Lavillette, Francois‐Loic Cosset, Se‐Hwan Yang, Chang Geun Lee, Hyun‐Tak Jin, Chang‐Min Kim, Mohamed Tarek M. Shata, Dong‐Hun Lee, Wolfram Pfahler, Alfred M. Prince, Young Chul Sung – 29 November 2005 – Immune correlates of protection against hepatitis C virus (HCV) infection are not well understood. Here we investigated 2 naive and 6 immunized chimpanzees before and after intravenous challenge, 12 weeks after the last immunization, with 100 50% chimpanzee infectious doses (CID50) of heterologous genotype 1b HCV.
Interleukin 6 upregulates myeloid cell leukemia‐1 expression through a STAT3 pathway in cholangiocarcinoma cells
Hajime Isomoto, Shogo Kobayashi, Nathan W. Werneburg, Steve F. Bronk, Maria Eugenia Guicciardi, David A. Frank, Gregory J. Gores – 29 November 2005 – Interleukin 6 (IL‐6) contributes to the pathogenesis of cholangiocarcinoma by upregulating myeloid cell leukemia‐1 (Mcl‐1), a key antiapoptotic Bcl‐2 family member protein. IL‐6 can alter gene transcription via Janus kinases (JAK) and signal transducer and activator of transcription (STAT) signal cascade. We examined this cascade in IL‐6 regulation of Mcl‐1 transcription in human cholangiocarcinoma cell lines.
Viral load as a predictor of progression of chronic hepatitis C?
Theo Heller, Leonard B. Seeff – 29 November 2005
Trends in health care resource use for hepatitis C virus infection in the United States
William C. Grant, Ravi R. Jhaveri, John G. McHutchison, Kevin A. Schulman, Teresa L. Kauf – 29 November 2005 – Chronic hepatitis C virus (HCV) infection affects approximately 3 million people in the United States and places tremendous demands on the health care system. As many observers have predicted, the disease burden continues to grow as the infected population ages. In this study, we analyzed inpatient data from the Healthcare Cost and Utilization Project, outpatient data from the National Ambulatory Medical Care Survey, and drug data from the Verispan Source Prescription Audit.
The effect of HLA mismatches, shared cross‐reactive antigen groups, and shared HLA‐DR antigens on the outcome after pediatric liver transplantation
Egbert Sieders, Bouke G. Hepkema, Paul M.J.G. Peeters, Elisabeth M. TenVergert, Koert P. de Jong, Robert J. Porte, Charles M.A. Bijleveld, Aad P. van den Berg, Simon P.M. Lems, Annette S.H. Gouw, Maarten J.H. Slooff – 28 November 2005 – The aim of this study was to analyze the effect of human leukocyte antigen (HLA) class I and HLA‐DR mismatching, sharing cross‐reactive antigen groups (CREGs), and sharing HLA‐DR antigens on the outcome after pediatric liver transplantation. Outcome parameters were graft survival, acute rejection, and portal fibrosis.
The role of liver transplantation in cystic fibrosis re‐examined
Maureen M. Jonas – 28 November 2005
Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation
Michelle Slifkin, Robin Ruthazer, Richard Freeman, Judy Bloom, Susan Fitzmaurice, Ralph Fairchild, Michael Angelis, Jeffrey Cooper, Laurie Barefoot, Richard Rohrer, David R. Snydman – 28 November 2005 – With improved cytomegalovirus (CMV) prophylaxis, CMV disease after liver transplantation has decreased dramatically, and patient and graft survival have improved. We examined the impact of CMV prophylaxis on biopsy proven rejection after orthotopic liver transplantation by analyzing data on 192 liver recipients over 5 years (1994‐1999).
Roles and pitfalls of transplantation in human porphyria
Neville Roy Pimstone – 28 November 2005
Recurrent hepatic sarcoidosis post‐liver transplantation manifesting with severe hypercalcemia: A case report and review of the literature
Cem Cengiz, Manuel Rodriguez‐Davalos, Graciela deBoccardo, M. Isabel Fiel, Gonzalo Rodriguez‐Laiz, Mark Kovacevic, Sukru Emre, Thomas Schiano – 28 November 2005 – Sarcoidosis is a systemic granulomatous disease primarily involving the lungs, lymph nodes, skin, eyes and nervous system; liver involvement is asymptomatic in most cases. However, once the patient develops clinical symptoms liver disease is usually progressive and may necessitate orthotopic liver transplantation. There are a few reports of asymptomatic recurrent sarcoidosis developing within the liver allograft.